Evidence from different screening programs indicated that the rate of congenital hypothyroidism (CH) was higher in pre-term and low-birth-weight (LBW) newborns than normal ones. Incomplete development of hypothalamicepituitary axis in this group of neonates results in the delayed rise of TSH and missing cases with CH. Hence, there is a great need for a practicable systematic screening method for proper diagnosis of CH in this group of neonates. In this review, we systematically reviewed papers with the following key words ([Congenital Hypothyroidism AND Screening AND Thyroxine AND Thyroid Stimulating Hormone AND Low Birth Weight AND Premature]) in international electronic databases including PubMed, Scopus, and Google Scholar. After quality assessment of selected documents, data of finally included papers were extracted. In this review, 1452 papers (PubMed: 617; Scopus: 714; Google scholar: 121) were identified through electronic database search. One hundred and ninety four articles were assessed for eligibility, from which 36 qualified articles were selected for final evaluation. From the reviewed articles, 38.9%, 11.11% and 8.3% recommended rescreening in this group of neonates, lowering the screening cutoff of TSH and using cutoffs according to the gestational age, respectively. Some of them (13.9%) recommended using both TSH and T4 for screening of preterm infants. After reviewing available data, we recommend repeating the screening test in pre-term, LBW and very-low-birth-weight (VLBW) infants at age of two, six and ten weeks by measuring TSH and FT4 levels simultaneously and considering TSH Z 10 mU/L as the cutoff level for positive and suspicious cases.
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Introduction
Congenital hypothyroidism (CH) is the most common cause of preventable mental retardation in children. Thus screening programs of CH have been established for better management of the disorder and preventing its related neurodevelopmental consequences. 1 The reported incidence rate of CH has significantly risen during past two decades. Suggested factors related to this high rate of CH occurrence are increased prevalence of CH and high rate of preterm infant births. 2, 3 Evidence from different screening programs indicated that the rate of CH was higher in pre-term and low-birthweight (LBW) newborns than normal ones due to insufficient development of hypothalamicepituitary axis. 4 Prevalence of this condition in very-low-birth-weight (VLBW) infants with birth weight of less than 1500 g has been approximately measured as 1 in 400 cases, which is significantly higher than its prevalence in full-term infants (1 in 4000 cases); however, only one-third of these infants can be diagnosed using the screening program. 5, 6 Therefore, it is critical to screen CH in preterm infant, to prevent and minimize neurodevelopmental impairment. Some studies suggest that screening in VLBW newborns should be repeated, whereas others recommended other strategies, including lowering screening TSH cutoff and etc. 5,7e9 Findings of different studies in this field are controversial. 10e12 It is difficult to interpret screening results of pre-term and extremely-low-birth-weight (ELBW) infants, and considering dissimilar findings of different studies. It was not possible to come to a general agreement on how to perform and repeat screening tests. In recent years, the survival rate of VLBW and ELBW infants has increased due to the improved neonatal care, which consequently results in higher incidence of CH. Therefore, there is need of a systematic highly sensitive screening program for early diagnosis of this condition in all infants at any gestational age. 12 Hence, considering the high prevalence of CH especially in pre-term and VLBW infants and its severe but preventable consequences, we aimed to try to come to a general conclusion on screening in pre-term infants using a systematic review of some related studies. We tried to come to an approach for screening and early diagnosis of CH especially in pre-term infants, in order to decrease the rate of false negative cases.
Materials and methods
In this study, we systematically reviewed papers related to screening of CH in preterm and LBW neonates up to December 2015.
The protocol of this review was approved by pediatrics review board and regional ethics committee of Isfahan University of Medical Sciences (research project number 393247).
In this review all studies reporting the protocol of their CH screening program's protocols and published in English without any time limitation until December 2015 were included. Studies which reported as conference abstracts or letters and those without a full text were excluded.
Search strategy, study selection and quality evaluation
In electronic search, key words including ([Congenital Hypothyroidism AND Screening AND Thyroxin AND Thyroid Stimulating Hormone AND Low Birth Weight AND Premature]) in international electronic databases including PubMed, Scopus, and Google Scholar were used.
Study selection and quality evaluation
All selected papers were reviewed and duplicate results were omitted. Two researchers reviewed all titles and abstracts individually and extracted related results. If the two researchers could not come to an agreement, a third researcher, a pediatric endocrinologist expert in the field of CH screening made the decision. Full texts of the articles were obtained and reviewed. Quality of the documents regarding the protocol of the screening, sampling method and size and laboratory methods and variables evaluation process was evaluated by two experts in the field of CH screening. Related articles were selected and data such as names of authors, location and year of study, size of samples, purpose, measured variables and findings were extracted. Considering the results and findings of different studies regarding screening of CH in preterm neonates, a final decision was prepared for screening of this group of neonates.
Results
In this review, 1452 papers (PubMed: 617; Scopus: 714; Google scholar: 121) were identified through electronic database search. One hundred and ninety four articles were assessed for eligibility, from which 36 qualified articles were selected for final evaluation (Fig. 1) .
Details of all selected studies are presented in Table 1 . According to the reports, normal TSH in three to six days after birth did not always imply normal function of the thyroid gland. TSH level of greater than 10 mU/L in the 2nd week of birth was diagnostically meaningful and TSH level of 10 mU/Le15 mU/L suggested "hypothyroidism with delayed TSH rise". FT4 and T4 levels became normal two to eight weeks after birth. 6,8e11,13e43 Regarding final recommendations for improving the screening of CH in prematurity, 38.9%, 11.11% and 8.3% recommended rescreening, lowering screening TSH cutoff and using cutoffs according to their gestational ages, respectively. Almost 14% of the studies recommended using both TSH and T4 measurements for this group of neonates. Two studies recommended delaying the screening program time in preterm infants. One did not confirm rescreening for CH screening in preterm infants. The reminders had no conclusive recommendations and only represented findings regarding the normalization time of TSH and T4 level or the rate of missing cases of CH in preterm infants.
Discussion
There is great need for a practicable systematic screening test with high sensitivity in order to reduce the missing cases of CH especially in preterm infants. Evidently preterm and LBW infants require special care and follow up. 10, 11 In this review we tried to systematically review previous works in this field and provide a comprehensive protocol for screening of these high-risk neonates.
Up to this date, few approaches have been introduced in order to reach this goal. One is reducing the cutoff value in order to increase the sensitivity of the screening test and another is a repetition of the screening test in LBW and preterm infants in order not to miss the delayed rise of TSH. Moreover, some studies have suggested considering normal ranges of thyroid hormones' levels based on gestational age, using both TSH and T4 measurement for CH screening or delaying the time of screening in preterm infants. 6,8e11,13e43 The findings of this review indicated that many studies (40%) recommended retesting of TSH or T4 for proper diagnosis of CH in preterm infants. 8,9,11,13,16,19,20,24e27,30e34,36,37,41,43 Articles identified through electronic database search (n=1452) Studies included in the review (n=36) Figure 1 Flowchart of study selection. Screening of CH in preterm infants Screening of CH in preterm infants A retrospective study -By using a TSH cutoff point of >10 mU/l for CH screening, a significant number of transient and permanent CH cases will be missed.
Screening of CH in preterm infants
and the effect on the number of children treated with levothyroxine -A lower cutoff point of 6 mU/l for TSH is recommended. Lowering the screening cutoff of TSH and using cutoffs according to the gestational age was the recommendation of 11.11% 32, 33, 38, 40 and 8.3% 15, 18, 40 of the reviewed studies, respectively. Some of the studies (13.9%) recommended using both TSH and T4 for screening of preterm infants 14, 19, 20, 39, 42 and some had no recommendation for CH screening and only reported their findings about the normalization time of TSH and T4 in this group of patients.
Currently, screening of CH is based on either evaluation of early TSH, evaluation of early T4 with a TSH follow-up, or evaluation of early TSH and early T4. As mentioned above, only one episode of evaluation of TSH levels may have the chance to miss delayed rise of TSH.
Recently Lee et al., 42 Muhammad et al. 39 and also some earlier studies emphasized measuring of both TSH and T4 for CH screening especially in preterm neonates. Evidence indicated that the screening based on measuring only TSH levels, which was common in many countries, did not have the ability to diagnose transient hypothyroidism. Therefore, measuring both FT4 and TSH in primary screening tests and following tests in order to increase the sensitivity are advisable and as a result a delayed rise of TSH could not be missed. 19, 26, 34, 37, 39, 41 Some researches such as Zhu, Adams and Kok et al. recommended using normal range references of hormone levels based on gestational age. 15, 18, 40 This was not practicable, as findings of different studies had variable results and using these references and their interpretation seems difficult. In addition, it seems that for different population the cutoffs will be different and there could be no single CH screening protocol for all communities.
Lowering the level of screening TSH cutoff is another recommendation for improving the CH screening among preterm infants. Mengreli et al. studied 311,390 screened infants in Greece and suggested that TSH cutoff level of greater than 20 mU/L could lead to missing 40 percent of pre-term infants with CH. 28 Results of some studies indicated that decreasing the TSH cutoff level to 10e12 mU/L reduces the rate of false negative cases and allows detection of an unsuspected number of neonates with CH. 27 Sirinvasan et al. evaluated the results of United Kingdom infants' screening program for five years which decreased the filter TSH cutoff level to 6 mU/L and considered TSH levels of 6 mU/Le20 mU/L as suspicious. They suggested that decreasing the cutoff level made it possible to run the test in only one session, at birth, and to repeat the test in gestational age at 36 weeks in newborns with suspicious results. 35 Moreover, in two separate studies on 2238 and 65,446 infants in England, Korada et al. proposed that, with decreasing TSH cutoff level to 6 mU/L, no cases of CH will be missed; therefore, repetition of the test would not be necessary. 25, 29 However, Bijarnia et al. proposed that the higher probability of hypothyroidism with delayed TSH rise in pre-term newborns, the greater would be the chance of both permanent and transient states of hypothyroidism; but the only way for a definitive diagnosis in these patients would be repetition of the screening test. 33 Despite what Korada et al. believed, Bijarnia proposed that decreasing the TSH cutoff level to 6 mU/L increased false positives by 28-folds, while some cases were still missed. 25, 29, 33 It seems that decreasing the TSH cutoff level to 6 mU/L drastically increases false positives, causing financial and psychological burden on the health system and infants' families; hence, choosing this threshold does not seem wise and affordable. Although decreasing the TSH cutoff level to lower than 20 mU/L seems inevitable in order not to miss CH cases, considering a cutoff level of 6 mU/L does not seem to be wise, as it drastically increases false positives. Thus, a cutoff level of 10 mU/L can improve the screening test for congenital hypothyroidism, whether in full-term or preterm infants. 36 Another suggested approach is a repetition of the screening test in order to find cases with delayed TSH rise that were missed using the primary test. However, the most suitable time for the 2nd test is disputed.
Chung et al., believed repetition of the test in pre-term newborns to be necessary, since infants could have a normal thyroid profile in the first days of their life. They recommended 2nd to 4th weeks of life as the most suitable time for the 2nd test. 26 In 2010 Chee et al. measured FT4 and TSH levels in low birth weight infants aged one-two and four weeks, and they proposed that TSH reached its maximum level on average at age of 2.4 weeks. 34 In 2012, Niwa's team studied on 47 VLBW infants in Kyoto Hospital, Japan, and they proposed that measuring TSH level at the age of two weeks could be helpful in evaluating transient hypothyroxinemia of prematurity and in prediction of the occurrence of delayed rise in TSH. 36 In Delange's study on 103 newborns, it was proposed that thyroid functional capacity of pre-term infants reached the same level as full-term newborns at the age of 4e6 weeks. 16 Tylek-Lemanska's study on 3854 LBW infants in Poland had the same finding. 24 Endocrinologists and pediatricians recommend diagnosing CH as soon as possible, and when the diagnosis of CH is definitive, they recommend starting the treatment as soon as possible, not later than age of four weeks. Therefore, it seems unwise to postpone the 2nd screening test to later than the 4th week, considering possible irreparable mental disorders.
Rooman et al. studied 263 infants with gestational age of 26e41 weeks and suggested that the best time for remeasuring FT4 and TSH levels was 2 weeks after birth. 19 Niwa also adds that the hypothalamicepituitary axis in LBW infants, develops at the age of about 2 weeks, therefore, this age is recommended to be the most suitable time for repetition of the screening test. 36 Considering the studies mentioned above and this systematic review of previous studies, two weeks seems to be the best age to perform the screening test, as the hypothalamicepituitary axis development is initiated at this age and the remaining maternal T4 disappears. It is recommended that the treatment start as soon as the diagnosis of CH is confirmed.
Conclusions and implications
Screening in the first days of life seems to be the most important step in the approach to CH and replacement of related deficient hormones, thus preventing consequences that cannot be remedied. Hence, optimizing the sensitivity of the screening test has great importance especially for this high risk group of neonates. Reviewing of present studies indicated that it was more favorable to retest premature infants for proper screening of CH, but considering the findings of all studies, we recommend the following:
1. Normal TSH during the first days of life in preterm infants could not rule out presence of CH. 2. We suggest repeating the screening of pre-term, LBW and VLBW infants at the age of two weeks, by measuring TSH and FT4 levels simultaneously and consider TSH Z 10 mU/L as the cutoff level for positive and suspicious cases. 3. T4 and FT4 should return to normal levels after 2e8 weeks and 4e12 weeks in LBW infants and ELBW infants, respectively. 4. Free T4 concentrations were remarkably stable after the first week of life despite wide variations in TSH concentrations (0.8e2.6 ng/dL). 5. A TSH level of 10e15 mU/L after an episode of normal TSH level could be indicative of delayed TSH rise which consequently increases the possibility of permanent or transient CH diagnosis. 6. A normal level of TSH in 3rd to 6th day of life does not always imply normal thyroid function. 7. TSH level decreases in 5th to 14th weeks of life. 8. It is recommended that the screening test be repeated in 2nd, 6th and 10th weeks of life. 9. Infants with gestational age of less than 28 weeks should be treated for 6 weeks despite their normal TSH level. 26 10. TSH level 20 mU/L in conjunction with any level of free T4 needs treatment. 11. Free T4 level <0.7 ng/dL during 3rd to 6th week of life in conjunction with a TSH level 10 mU/L needs treatment. 12. TSH 10e20 mU/L with normal FT4 for two times needs treatment. 26, 36, 40, 42, 44, 45 
